Cargando…

The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients

Detalles Bibliográficos
Autores principales:	Soni, Shubham, Dyck, Jason R.B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Canadian Cardiovascular Society. Published by Elsevier Inc. 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378495/ https://www.ncbi.nlm.nih.gov/pubmed/32717278 http://dx.doi.org/10.1016/j.cjca.2020.07.230

Ejemplares similares

Use of SGLT‐2 inhibitor in COVID‐19: A cautionary tale
por: Yousaf, Zohaib, et al.
Publicado: (2021)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

SGLT-2 inhibitors for COVID-19 — A miracle waiting to happen or just another beat around the bush?
por: Chatterjee, Subhankar
Publicado: (2020)

SGLT2 Inhibitors: A New Dawn for Recurrent/Refractory Cirrhotic Ascites
por: Gao, Yuan, et al.
Publicado: (2021)

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?
por: Bernardi, Marco, et al.
Publicado: (2023)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

Meta‐analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF
por: Qiu, Mei, et al.
Publicado: (2021)

Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor
por: Miyamoto, Yasunori, et al.
Publicado: (2021)

Serine protease inhibitors could be of benefit in the treatment of COVID-19 disease
por: Okeahialam, Basil N.
Publicado: (2021)

Fournier's Gangrene and Sodium-glucose Co-transporter 2(SGLT2) Inhibitors: Our Experience
por: Dass, Ashwitha S., et al.
Publicado: (2019)

Letter Regarding “Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations”
por: Rico-Fontalvo, Jorge, et al.
Publicado: (2022)

DELIVER: Extending the benefits of SGLT-2 inhibitors
por: Samaan, Kerollos, et al.
Publicado: (2023)

Euglycaemic ketoacidosis after abdominal surgery: Implications of SGLT2 inhibitors for anaesthesiologists – A case study
por: Kartha, Anandajith P., et al.
Publicado: (2023)

SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic
por: Sung, Jasper, et al.
Publicado: (2018)

Do SGLT-2 Inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?
por: De Pascalis, Antonio, et al.
Publicado: (2020)

The potential benefits of antihistamine therapy and exercise rehabilitation in women with post-COVID-19 syndrome
por: Oudjedi, Adda
Publicado: (2022)

Suggestions for the focus of OHCA meta-analysis in the COVID-19 era
por: Ahn, Chiwon
Publicado: (2022)

The Impact of COVID-19 on Diabetes Research in Canada
por: Dyck, Jason R.B.
Publicado: (2020)

In Reply to ‘Do SGLT-2 Inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?’
por: Neuwirt, Hannes, et al.
Publicado: (2020)

Strong Association Between Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors
por: Yanagawa, Tatsuo
Publicado: (2018)

Stroke in a young adult with mild COVID-19 suggesting endotheliitis
por: Crippa, S., et al.
Publicado: (2020)

Suggesting Ritonavir against COVID-19/SARS-CoV-2
por: Choudhury, Shuvasish, et al.
Publicado: (2020)

Expert suggestion for diabetes management during the recent COVID‐19 pandemic
por: Wang, Weiqing, et al.
Publicado: (2022)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
por: Evans, Marc, et al.
Publicado: (2019)

ARNI and SGLT2i: a promising association to be used with caution
por: Herbst, Andrea, et al.
Publicado: (2020)

SGLT2 inhibitor therapy and pulmonary artery pressure in patients with chronic heart failure—further evidence for improved hemodynamics by continuous pressure monitoring
por: Kirschbaum, Klara, et al.
Publicado: (2021)

Some Practical Suggestions for Mitigation of Psychological Burden of Hospitalized Patients with COVID-19
por: Shaygan, Maryam, et al.
Publicado: (2021)

Covid-19-induced coagulopathy and observed benefits with anticoagulation
por: Karimzadeh, Sedighe, et al.
Publicado: (2020)

COVID-19 and Alcohol Consumption: No Preventive or Therapeutic Benefits
por: Shrivastava, Saurabh RamBihariLal, et al.
Publicado: (2020)

Antenatal corticosteroids and COVID-19: balancing benefits and harms
por: Liauw, Jessica, et al.
Publicado: (2020)

Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy
por: Xi, Yangbo, et al.
Publicado: (2022)

Evidence suggests children are being left behind in COVID-19 mental health research
por: Racine, Nicole, et al.
Publicado: (2020)

Suggestions for safety and protection control in Department of Nuclear Medicine during the outbreak of COVID-19
por: Zhang, Xiao, et al.
Publicado: (2020)

An update on the potential health benefits of carotenes
por: Kim, Jae Kwang
Publicado: (2016)

Current potential health benefits of sulforaphane
por: Kim, Jae Kwang, et al.
Publicado: (2016)

Plant products in reducing spread of coronavirus infection (COVID-19)
por: Math, M.V., et al.
Publicado: (2021)

COVID-19 diagnoses in South East London peaked before the UK suggesting early measures reduced transmission
por: Aylwin, Simon J.B., et al.
Publicado: (2020)

Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2q10h153bnp6kafa452lnj0ofb